IRCT138804022067N1已完成未知
Combined therapy of silymarin and desferrioxamine in patients with b-thalassemia major: a randomized double-blind clinical trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 years 至 no limit（—）
- 性别
- All
入选标准
- •Inclusion Criteria: Presence of major Beta-thalassemia, age 12 years or older, iron overload condition (with serum ferritin levels between 1000-5000 ng/mL) during 6 months prior to study, regular deferoxamine administration (50 mg/kg), receiving continuous blood transfusions maintained at a hemoglobin level of 9.5 g/dl, negative CRP test at the beginning of the study Exclusion criteria: Presence of hepatitis B or C infection, positive HIV test, gastrointestinal problemss preventing absorption of an oral medication presence of chronic renal or heart failure, iron chelating therapy with iron chelators other than desferrioxamine, pregnancy
排除标准
- 未提供
研究者
相似试验
Unknown
2 期
Therapeutic Effects of Silymarin in Patients With B-thalassemia MajorBeta-thalassemia MajorIron OverloadNCT00999349Isfahan University of Medical Sciences140
已完成
2 期
Treatment of iron overload in thalassemia patientsThalassemia.Beta thalassaemiaIRCT2016041627412N1Vice Chancellor for research of Urmia University of Medical Sciences36
已完成
2 期
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron OverloadCardiac Iron OverloadNCT01254227Novartis Pharmaceuticals60
尚未招募
2 期
Efficacy and safety of triple iron chelator (deferoxamine, deferasirox, and deferiprone) versus dual iron chelator (deferoxamine and deferasirox) combination therapy for reducing iron overload in transfusion-dependent beta-thalassaemia with very high iron overload.ThalassaemiaSLCTR/2023/010Prof Anuja Premawardhena
已完成
3 期
The effect of silymarin on methadone poisoningIRCT20210216050377N1Shahre-kord University of Medical Sciences64